Growth Charts for Non-Growth Hormone Treated Prader-Willi Syndrome

Merlin G. Butler, MD, PhD, Jaehoon Lee, PhD, Ann M. Manzardo, PhD, June-Anne Gold, MD, Jennifer L. Miller, MD, Virginia Kimonis, MD, Daniel J. Driscoll, MD, PhD

abstract

OBJECTIVE: The goal of this study was to generate and report standardized growth curves for weight, height, head circumference, and BMI for non-growth hormone–treated white male and female US subjects with Prader-Willi syndrome (PWS) between 3 and 18 years of age and develop standardized growth charts.

METHODS: Anthropometric measures ($N = 133$) were obtained according to standard methods from 120 non–growth hormone–treated white subjects (63 males and 57 females) with PWS between 3 and 18 years of age. Standardized growth curves were developed for the third, 10th, 25th, 50th, 75th, 90th, and 97th percentiles by using the LMS method for weight, height, head circumference, and BMI for PWS subjects along with the normative third, 50th, and 97th percentiles from national and international growth data. The LMS smoothing procedure summarized the distribution of the anthropometric variables at each age using three parameters: power of the Box-Cox transformation $\lambda$ ($L$), median $\mu$ ($M$) and coefficient of variation $\delta$ ($S$).

RESULTS: Weight, height, head circumference, and BMI standardized growth charts representing 7 percentile ranges were developed from 120 non–growth hormone–treated white male and female US subjects with PWS (age range: 3–18 years) and normative third, 50th, and 97th percentiles from national and international data.

CONCLUSIONS: We encourage the use of syndrome-specific growth standards to examine and evaluate subjects with PWS when monitoring growth patterns and determining nutritional and obesity status. These variables can be influenced by culture, individual medical care, diet intervention, and physical activity plans.

WHAT’S KNOWN ON THIS SUBJECT: Syndrome-specific standardized growth curves are not currently available for non–growth hormone–treated subjects with Prader-Willi syndrome and are required for monitoring growth and development in this rare obesity-related disorder.

WHAT THIS STUDY ADDS: Standardized growth curves were useful in monitoring growth and development in these subjects with Prader-Willi syndrome and for the management of growth hormone treatment of both genders, particularly those aged 3 to 18 years.

DOI: 10.1542/peds.2014-1711

Accepted for publication Oct 1, 2014
Prader-Willi syndrome (PWS) is a classic genetic disorder characterized by central hypotonia with a poor suck and feeding difficulties that is found in infancy and accompanied by failure to thrive, hypogonitalism/hypogonadism, and growth hormone deficiency. In early childhood, hyperphagia develops, which leads to obesity if left uncontrolled. Additional findings include an IQ of 65 and behavioral problems (eg, rigidity, compulsions, temper tantrums, self-injury), as well as hypopigmentation, small hands and feet, short stature, and a characteristic facial appearance.\(^1\)–\(^4\)

PWS occurs in \(~1\) in \(15\,000\) live births and is estimated to affect \(~400\,000\) people worldwide. It is considered the most common syndromic cause of life-threatening obesity\(^1\) and arises sporadically in most cases. It is caused by loss of paternally expressed genes in the chromosome 15q11-q13 region, usually due to a deletion in \(~70\%\) of affected subjects.\(^1\)–\(^4\) Approximately \(25\%\) of cases have maternal disomy 15 or both 15s from the mother, with the remaining \(5\%\) resulting from a defect in the imprinting center controlling the activity of genes in this chromosome region. Life span in PWS is highly variable worldwide depending on the quality of medical and social care, but it is expected to be shortened due to disease-associated physical and neurologic problems. The chance of recurrence is high for deletion and maternal disomy subtypes (<1%), but those with an imprinting center defect may have a recurrence risk as high as 50%.\(^1\)–\(^4\)

Classically, 2 distinct stages of clinical course development have been reported in PWS: the first stage is characterized by profound hypotonia and failure to thrive in infancy and the second stage is characterized by onset of hyperphagia and subsequent obesity in early childhood with food foraging and behavioral problems. Recently, a multicenter study identified 7 different nutritional phases and subphases. The first phase describes the PWS infant with hypotonia with or without failure to thrive (age birth to 15 months); phase 2 is associated with weight gain without a significant change in appetite but followed by weight gain with an increased interest in food (median age of onset: 4.5 years); phase 3 is characterized by hyperphagia, food seeking, and lack of satiety (median age of onset: 8 years); and phase 4 indicates that an insatiable appetite may no longer exist and occurs in some adults with this obesity-related disorder.\(^5\)

Growth hormone therapy is now frequently prescribed, often in early infancy or by early childhood once the diagnosis of PWS has been confirmed. Growth hormone treatment can lead to improved changes in body composition, physical activity, and growth velocity. Because there are syndrome-specific standardized growth charts, our goal was to provide new growth charts of weight, height, head circumference, and BMI for non–growth hormone–treated subjects with PWS between 3 and 18 years of age that can be used in the clinical setting and be helpful in monitoring growth hormone treatment in PWS. These standardized charts would replace the PWS growth charts reported by Butler and Meaney in 1991 of selected anthropometric measurements from subjects aged 2 to 22 years from an earlier era. Our charts are similar to the standardized growth charts recently developed for non–growth hormone–treated PWS infants between age 0 and 3 years.\(^7\)–\(^8\)

**METHODS**

**Subjects**

Growth data were collected from 120 PWS subjects (63 males, 57 females) with genetic confirmation of PWS and no current or previous growth hormone treatment. The data were collected following standardized protocols and using an investigator-approved manual of operation. The majority of subjects were recruited from 2003 to 2013 as a component of a large rare disease consortium on PWS research at sites representing 4 states (Florida, Tennessee, Kansas, and California). The subjects were prospectively and consecutively enrolled after genetic confirmation, often from those followed up previously in the clinical setting. Seventy-six (63%) subjects with PWS had a 15q11-q13 deletion, 42 (35%) had maternal disomy 15, and 2 (2%) had an imprinting defect.

The genetic testing included chromosome analysis with fluorescence in situ hybridization, chromosome 15 methylation-specific multiplex ligation-dependent probe amplification copy number and methylation testing, genotyping with polymorphic chromosome 15 markers of proband and parental DNA, and/or chromosomal microarray studies. The inclusion criteria required genetic confirmation of PWS for each subject before growth data were used for the growth chart development; the only exclusion criteria were current or previous growth hormone treatment. All PWS participants were cared for by clinicians, geneticists, and dietitians following medical management recommendations\(^2\) and with expertise treating subjects with PWS. Calorie-restricted diets at 60% to 80% of normal for age and activity were followed, and exercise plans (eg, 30 minutes of walking per day) were established for each participant depending on his or her age and obesity status.\(^2\)–\(^5\)\(^,\)\(^9\)

Ten subjects had repeated measurements for weight, height, and/or head circumference (7 subjects with 2 measurements; 3 subjects with 3 measurements), which produced a total of 133 data points distributed from 3 to 18 years of age. Approximately 56% of the data were available from 3 to 10 years;
25% from 10 to 15 years; and 19% from 15 to 18 years of age. For comparison purposes, the 3 normative percentile curves (third, 50th, and 97th) for each growth chart were plotted from data of normal control subjects from the Centers for Disease Control and Prevention (www.cdc.gov/growthcharts/percentile_data_files.htm) for height, weight, and BMI and from Nellhaus for head circumference.

Methods and Measurements
The subjects’ anthropometric measurements were obtained by the authors according to standard techniques and following established protocols. The measurements consisted of weight, height, and head circumference. Height was measured to the nearest 0.1 cm in a standing position with a sliding stadiometer fixed to the wall. Head (occipital–frontal) circumference was measured to the nearest millimeter with a steel tape. Weight was recorded to the nearest 0.01 kg with a calibrated balanced beam or electronic digital scale.

Growth reference charts are widely used to observe or track an individual’s clinical measurements in the context of population values. Growth charts for weight, height, and head circumference, and BMI were developed for each gender by using the LMS method as used previously in the development and reporting of standardized growth curves. The LMS method is a standard technique for constructing age-related growth references and summarizes the distribution of an anthropometric variable Y at each value of a covariate (age) in terms of 3 parameters: Box-Cox power λ (L), median μ (M), and coefficient of variation σ (S):

\[ z = \frac{(Y/\mu)^\lambda - 1}{\lambda \times \sigma} \]

The outcome is SD or z scores having a symmetric and nearly standard normal distribution. The optimal value of Box-Cox power to transform the data into near-normality is estimated over the range of age, and its trend is summarized by an L curve. Similarly, the estimated medians and coefficients of variation are summarized by M and S curves over the age range, respectively. Penalized likelihood estimation finds the L, M, and S curves as cubic smoothing splines, and the degree of smoothing is indicated in terms of equivalent degrees of freedom (edf).

Using LMS Chartmaker 2.4, we created a set of percentile curves (third, 10th, 25th, 50th, 75th, 90th, and 97th) for weight, height, head circumference, and BMI according to gender. The deviance test was used to determine the best models, and the Q test was conducted to evaluate the model fit by inspecting the distributions of the calculated z scores.

RESULTS
The distributional properties of the anthropometric variables did not differ over the ranges of age (ie, 3–10, 10–15, 15–18 years) between male or female subjects with the 15q11-q13 deletion and those with other genetic defects, including maternal disomy 15. The properties were therefore combined in the production of individual growth charts for each gender. The normality of data held, except for weight measures in male subjects, which required Box-Cox transformation. Figures 1, 2, 3, and 4 show the percentile curves of weight, height, head circumference, and BMI for non-growth hormone–treated subjects with PWS between 3 and 18 years of age; the percentile curves for normal control subjects are also shown.

For weight in male subjects (edf = 1, 2, 4, 3), the normative 97th percentile generated from the Centers for Disease Control and Prevention national growth data14 followed between the 25th and 50th percentiles for PWS beginning at 4 years of age and continued to 13 years, when the normative 97th percentile was similar to the PWS 50th percentile. The PWS 75th percentile was consistently above the normative 97th percentile throughout all ages between 3 and 18 years. For weight in female subjects (edf = 1, 3, 1), the normative 97th percentile followed between the 50th and 75th percentiles for PWS until 10 years of age and between the 75th and 90th percentile in PWS until 15 years of age, when normative weight leveled off. Weight continued rapidly upward for all percentiles for female subjects with PWS from 3 to 18 years. At 18 years of age, the normative 97th percentile was equal to the PWS 50th percentile.

For height in male subjects (edf = 1, 4, 3), the normative 50th percentile ranged between the 50th and 75th percentile for PWS between 3 and 12 years of age, with height tapering off in PWS by 18 years of age, at which time the normative 50th percentile was equal to the PWS 97th percentile. For height in female subjects (edf = 1, 4, 3), the normative 50th percentile was between the PWS 75th and 90th percentiles until 10 years of age; thereafter, all PWS percentiles tapered off. For example, the normative third percentile was equal to the PWS 75th percentile by 18 years of age, and the normative 50th percentile was equal to the PWS 97th percentile by this age.

For head circumference in male subjects (edf = 1, 4, 2), the normative 50th percentile fell between the 50th and 75th percentiles for PWS from 3 to 18 years of age and approached the PWS 50th percentile by 18 years of age. The normative third percentile was similar to the PWS 10th percentile from 6 years of age or later. For head circumference in female subjects (edf = 1, 2, 5, 1), the normative 50th percentile was similar to the 50th percentile for PWS from 3 to 11 years of age, at which time the normative 50th percentile continued to increase with age while the PWS 50th percentile tapered off. By 18 years of age, the normative 50th percentile was equal to the PWS 75th percentile at 18 years of age. The
FIGURE 1
Standardized curves for weight of non-growth hormone–treated subjects (male subjects [upper] and female subjects [lower]) with PWS (solid lines) and normative percentile ranges (shaded area) with normative 97th to 50th percentiles in dark shading and 50th to third percentiles in light shading.
FIGURE 2
Standardized curves for height of non-growth hormone-treated subjects (upper) and female subjects (lower) with PWS (solid lines) and normative percentile ranges (shaded area) with normative 97th to 50th percentiles in dark shading and 50th to third percentiles in light shading.

FIGURE 2
Standardized curves for height of non-growth hormone-treated subjects (upper) and female subjects (lower) with PWS (solid lines) and normative percentile ranges (shaded area) with normative 97th to 50th percentiles in dark shading and 50th to third percentiles in light shading.
FIGURE 3
Standardized curves for head circumference of non–growth hormone–treated subjects (male subjects [upper] and female subjects [lower]) with PWS (solid lines) and normative percentile ranges (shaded area) with normative 97th to 50th percentiles in dark shading and 50th to third percentiles in light shading.
FIGURE 4
Standardized curves for BMI weight of non-growth-hormone treated subjects (male subjects [upper] and female subjects [lower]) with PWS (solid lines) and normative percentile ranges (shaded area) with normative 97th to 50th percentiles in dark shading and 50th to third percentiles in light shading.
normative third percentile was comparable to the 10th percentile for female subjects with PWS until 11 years of age, which then increased with age to equal the PWS 25th percentile by 16 years of age.

For BMI in male subjects (edf = 1,3,1), the normative 97th percentile was comparable to the 25th percentile for PWS from 6 to 18 years of age; however, at age 3 years, the normative third percentile was comparable to the 25th percentile for PWS, indicating the failure-to-thrive pattern of development seen in PWS at an early age. For BMI in female subjects (edf = 1,3,1), the normative 50th percentile ranged between the third (at 18 years) and the 10th (at 5 years) percentiles for PWS from age 5 to 18 years, again indicating the hyperphagia and increased weight gain, which are common in early childhood and beyond in PWS if caloric intake is not controlled. The normative 97th percentile ranged between the 25th and 50th percentiles in PWS throughout the age range from 3 to 18 years.

**DISCUSSION**

All PWS participants were white, with no current or previous growth hormone treatment. They were recruited in clinics from 4 states specializing in the diagnosis, treatment, and care of subjects with this rare disorder. Standardized growth curves for height, weight, head circumference, and BMI were generated from non–growth hormone–treated male and female subjects with a genetically confirmed diagnosis of PWS between 3 and 18 years of age and from healthy control subjects from the literature or databases. A deceleration of linear growth in PWS was documented specifically at the age of normal puberty relative to normative data by examining the standardized height curves in non–growth hormone–treated subjects. Although our PWS growth data were primarily cross-sectional in nature, with 133 data points from 120 PWS participants, an exaggerated increase in weight gain with age was seen in both PWS male and female subjects compared with normative data indicative of this obesity-related disorder. Weight and BMI data used to develop standardized curves can be affected by the level of physical activity and degree of monitoring of caloric intake, which may vary per individual (ie, some subjects are more motivated to lose and maintain weight loss and can vary from year to year). No significant differences have been reported in male or female subjects with PWS and the typical 15q11-q13 deletion or those with the nondeletion status (ie, maternal disomy 15 or a defect of the imprinting center controlling the activity of imprinted genes). Our PWS participants do not necessarily reflect the natural history in this syndrome because our health care program at the recruitment sites included restricted caloric intake and planned physical activity to control weight.

No subject had a current or history of growth hormone use, but other factors could affect growth measures in addition to diet and energy expenditure, including sex steroid use, endocrine disturbances (eg, thyroid, pancreas, adrenal), and medications (eg, atypical antipsychotic agents). All subjects with PWS in our study were young (age range: 3–18 years), and the use of sex steroids was infrequent (<10% of subjects) and few were prescribed atypical antipsychotics. In addition, <20% of subjects had a history of diabetes mellitus and <10% were treated for thyroid or adrenal gland problems, reflecting reported frequencies in the PWS population.2-19

Recently, Butler et al20 reported that the growth hormone receptor gene (GHR) in US children with PWS with the common exon 3 deletion polymorphism correlated with advanced height acceleration (similar to children without PWS also receiving growth hormone) compared with those without the GHR gene polymorphism. These observations should be more extensively studied in additional patients and be monitored for clinical outcomes. Growth hormone treatment that leads to improvement in stature, body composition, and metabolism from infancy through young adulthood in PWS stresses the need for syndrome-specific standardized growth charts for use in monitoring longitudinal growth patterns and response to nutritional and hormone intervention.

Anthropometric or growth standards have been generated for several syndromes and used in the clinical setting for medical management. Specifically, the standardized growth charts developed for infants (0–3 years of age) with PWS are currently in use for monitoring growth parameters and development in this rare genetic obesity-related disorder. Other published growth charts for PWS have been generated. For example, Butler et al6 reported charts from 71 US white subjects with PWS aged 2 to 22 years, and Hauffa et al26 reported charts from German PWS subjects aged 0 to 18 years. The new PWS standardized graphs in our report show similar results with standardized curves from previous reports on US white subjects generated >2 decades ago and before growth hormone treatment. Most medical centers nationwide now offer specialized care for treating the unique features seen in PWS. Specifically, the new PWS height curves are similar to the charts previously reported by Butler and Meaney6 and the German PWS graphs reported by Hauffa et al. However, according to the new charts for white, US male subjects with PWS, white subjects from the United States may be heavier than German PWS male subjects at comparable ages.

The increased rate of growth in height noted during normal puberty is absent in both male and female subjects with PWS when comparing the standardized data, and this
impaired growth (short stature secondary to growth hormone deficiency) and complicated further by failure to thrive and feeding difficulties in infancy. The onset of hyperphagia in PWS usually occurs in early childhood and leads to rapid weight gain and subsequent obesity, as illustrated by distortions observed in the newly developed growth patterns relative to normative data. Diagnosis is needed at an early age, with caloric restriction and increased physical activity to avoid the onset of obesity and medical comorbidities. Fortunately, better awareness now exists in the medical community, and more appropriate genetic testing methods are available for an early diagnosis and treatment with growth hormone for affected individuals with PWS. With early diagnosis and treatment, the quality of life and clinical outcome in PWS have improved with support of standardized growth curves used by the clinician and dietitian in the care of infants with PWS. However, those health care providers regularly supplying medical care for PWS subjects recognize the need for current standardized growth charts between 3 and 18 years of age to monitor nutrition, growth rate, and obesity. In addition, standardized growth charts can be used to guide growth hormone therapy and monitor for accelerated growth rate, orthopedic problems such as scoliosis, or other clinical features seen in this rare obesity-related genetic disorder. To meet those needs, if they should arise, the authors encourage the use of these newly established syndrome-specific standardized growth charts in the clinic setting for the medical care and treatment of subjects with PWS.

CONCLUSIONS

Growth charts help optimize medical care and treatment in subjects with rare disorders such as PWS who have

ACKNOWLEDGMENTS

We thank Carla Meister for preparation of the manuscript.

REFERENCES


Growth Charts for Non-Growth Hormone Treated Prader-Willi Syndrome
Merlin G. Butler, Jaehoon Lee, Ann M. Manzardo, June-Anne Gold, Jennifer L. Miller, Virginia Kimonis and Daniel J. Driscoll
Pediatrics 2015;135:e126
DOI: 10.1542/peds.2014-1711 originally published online December 8, 2014;
health outcomes across groups, reflecting a potential explanatory role of factors such as daily hardships, caregiver depression, and HIV-related stigma.”

doi:10.1542/peds.2015-0753


doi:10.1542/peds.2015-0804


An error occurred in the article by Butler et al, titled “Growth Charts for Non-growth Hormone Treated Prader-Willi Syndrome” published in the January 2015 issue of *Pediatrics* (2015;135(1):e126–e135; doi:10.1542/peds.2014-1711). On page e129, Fig 1, A and B, the third percentile line is missing for both the male and female subjects. This line is lower but closely parallels the other percentile lines.

In the Figure Legend for Fig 1, this reads: “(male subjects [upper] and female subjects [lower])”. This should have read: “(male subjects [left] and female subjects [right])”.

doi:10.1542/peds.2015-0826
Growth Charts for Non-Growth Hormone Treated Prader-Willi Syndrome
Merlin G. Butler, Jaehoon Lee, Ann M. Manzardo, June-Anne Gold, Jennifer L. Miller, Virginia Kimonis and Daniel J. Driscoll

Pediatrics 2015;135:e126
DOI: 10.1542/peds.2014-1711 originally published online December 8, 2014;

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://pediatrics.aappublications.org/content/135/1/e126

An erratum has been published regarding this article. Please see the attached page for:
http://pediatrics.aappublications.org/content/135/5/946.2.full.pdf